1 / 2

Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04

Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04 - KALESOLO - MOST - HIV-NAT 077. HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy.

seth-emerson
Download Presentation

Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch to LPV/r monotherapy • - Pilot LPV/r • - M03-613 • - American Study • - KalMo • - OK • - OK04 • - KALESOLO • - MOST • - HIV-NAT 077

  2. HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy • 50 HIV-1 infected Thaï children failing first line NRTIs + NNRTI, switched to double ritonavir-boosted PIs for 144 weeks (LPV/r + SQV = 90%) ; 40 children with virological suppression (HIV-1 RNA < 50 c/mL at least 3 months apart) switched to LPV/r 230/57.5 mg/m2 bid monotherapy • Female: 50%, Median age: 11.7 years • At W48 • HIV-1 RNA < 50 c/mL: 72.5% • Still on LPV/r monotherapy, N = 31 (78%) • Returned to double boosted PIs due to failure, N = 9 • No emergence of major protease resistance mutations • Conclusion • Simplifying second-line treatment from double-boosted PI therapy to LPV/r monotherapy allows for sustain virologic suppression in the majority of children after 48 weeks of follow-up Bunupuradah T, AIDS 2011;25:315-23 HIV-NAT 077

More Related